PMH13 ESTIMATING THE BENEFIT OF LONG-ACTING INJECTABLES FOR SCHIZOPHRENIA TREATMENT IN RWANDA USING A ONE-YEAR COST-CONSEQUENCE MODEL
May 1, 2019, 00:00 AM
10.1016/j.jval.2019.04.1058
https://www.valueinhealthjournal.com/article/S1098-3015(19)31250-1/fulltext
Section Title :
Section Order :
10588
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)31250-1&doi=10.1016/j.jval.2019.04.1058